---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-14T14:18:23.686771'
end_time: '2026-02-14T14:27:35.568042'
duration_seconds: 551.88
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: IRF4
  gene_symbol: IRF4
  uniprot_accession: Q15306
  protein_description: 'RecName: Full=Interferon regulatory factor 4 {ECO:0000303|PubMed:15489334,
    ECO:0000303|PubMed:8921401}; Short=IRF-4; AltName: Full=Lymphocyte-specific interferon
    regulatory factor {ECO:0000303|PubMed:9326949}; Short=LSIRF; AltName: Full=Multiple
    myeloma oncogene 1 {ECO:0000303|PubMed:9326949}; AltName: Full=NF-EM5;'
  gene_info: Name=IRF4 {ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8921401};
    Synonyms=MUM1 {ECO:0000303|PubMed:9326949};
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the IRF family. {ECO:0000255|PROSITE-
  protein_domains: Interferon_reg_fac_CS. (IPR019817); Interferon_reg_fact_DNA-bd_dom.
    (IPR001346); Interferon_reg_factor-3. (IPR019471); SMAD-like_dom_sf. (IPR017855);
    SMAD_FHA_dom_sf. (IPR008984)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 40
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q15306
- **Protein Description:** RecName: Full=Interferon regulatory factor 4 {ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8921401}; Short=IRF-4; AltName: Full=Lymphocyte-specific interferon regulatory factor {ECO:0000303|PubMed:9326949}; Short=LSIRF; AltName: Full=Multiple myeloma oncogene 1 {ECO:0000303|PubMed:9326949}; AltName: Full=NF-EM5;
- **Gene Information:** Name=IRF4 {ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8921401}; Synonyms=MUM1 {ECO:0000303|PubMed:9326949};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the IRF family. {ECO:0000255|PROSITE-
- **Key Domains:** Interferon_reg_fac_CS. (IPR019817); Interferon_reg_fact_DNA-bd_dom. (IPR001346); Interferon_reg_factor-3. (IPR019471); SMAD-like_dom_sf. (IPR017855); SMAD_FHA_dom_sf. (IPR008984)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "IRF4" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'IRF4' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **IRF4** (gene ID: IRF4, UniProt: Q15306) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q15306
- **Protein Description:** RecName: Full=Interferon regulatory factor 4 {ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8921401}; Short=IRF-4; AltName: Full=Lymphocyte-specific interferon regulatory factor {ECO:0000303|PubMed:9326949}; Short=LSIRF; AltName: Full=Multiple myeloma oncogene 1 {ECO:0000303|PubMed:9326949}; AltName: Full=NF-EM5;
- **Gene Information:** Name=IRF4 {ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:8921401}; Synonyms=MUM1 {ECO:0000303|PubMed:9326949};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the IRF family. {ECO:0000255|PROSITE-
- **Key Domains:** Interferon_reg_fac_CS. (IPR019817); Interferon_reg_fact_DNA-bd_dom. (IPR001346); Interferon_reg_factor-3. (IPR019471); SMAD-like_dom_sf. (IPR017855); SMAD_FHA_dom_sf. (IPR008984)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "IRF4" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'IRF4' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **IRF4** (gene ID: IRF4, UniProt: Q15306) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: Human IRF4 (UniProt Q15306)

Identity, Domains, and Definitions
- Identity verification: IRF4 (also known as MUM1/LSIRF) is a human interferon regulatory factor family transcription factor, largely restricted to the immune system. It is induced primarily by antigen receptor signaling (TCR/BCR), IL-4, CD40, and LPS, rather than by type I/II interferons, consistent with UniProt Q15306 annotations and IRF family membership (DBD plus IAD) (lu2023regulatoryeffectsof pages 1-2, gabele2025elucidatingtherole pages 15-17, gabele2025elucidatingtherolea pages 15-17).
- Domain architecture: IRF4 contains an N‑terminal tryptophan‑rich DNA‑binding domain (DBD) that recognizes ISRE-like GAAA motifs, and a C‑terminal IRF‑associated domain (IAD) mediating homo/hetero‑dimerization. Literature also describes an autoinhibitory region and a nuclear localization signal. Structural/biophysical studies of the human IRF4 DBD and mutants support this architecture and its functional consequences (e.g., altered DNA-binding kinetics and nuclear partitioning) (tatum2025structuralbiophysicaland pages 1-2, tatum2025structuralbiophysicaland pages 20-23, gabele2025elucidatingtherole pages 15-17, gabele2025elucidatingtherolea pages 15-17). URLs/dates: Frontiers Immunology, Feb 2023, https://doi.org/10.3389/fimmu.2023.1086803; bioRxiv, Mar 2025, https://doi.org/10.1101/2025.03.12.642038.

Cellular Localization
- IRF4 functions as a nuclear transcription factor. DBD mutant analyses show changes in nuclear partitioning (e.g., K123R nearly entirely nuclear), reinforcing nuclear localization as essential to activity (bioRxiv preprint; interpret with caution pending peer review) (tatum2025structuralbiophysicaland pages 20-23). URL/date: bioRxiv, Mar 2025, https://doi.org/10.1101/2025.03.12.642038.

Primary Molecular Function and DNA-Binding Mechanisms
- IRF4 is a context‑dependent transcription factor with intrinsically weak solo DNA binding. It acquires specificity and affinity via composite elements and partner TFs: with PU.1/Spi-B at EICEs in B cells, and with AP‑1 family (e.g., BATF/Jun) at AICEs in T cells; partner sets include AHR, FOXP3, IRF8 in Treg/Th17 contexts. ChIP-seq/proteomic interactome mapping in T cells shows enhancer‑biased binding and extensive partner-dependence for target selection (bioRxiv, Sep 2023) (gabele2023unveilingirf4steeredregulation pages 17-19, gabele2023unveilingirf4steeredregulation pages 12-14, gabele2025elucidatingtherole pages 15-17, gabele2025elucidatingtherolea pages 15-17). URL/date: bioRxiv, Sep 2023, https://doi.org/10.1101/2023.09.14.557376.
- Induction and upstream control: TCR signaling (notably via NF‑κB/c‑Rel) drives IRF4 expression in a dose‑dependent fashion; IRF4 is further integrated with mTOR, ITK, NFAT, and STAT3 signaling, and cross‑regulated by lineage TFs (T‑bet, GATA3, RORγt, FOXP3) (gabele2025elucidatingtherole pages 15-17, gabele2025elucidatingtherolea pages 15-17). URL/date: 2025 thesis/overview (unknown journal; mechanistic details concordant with 2023–2024 primary studies listed elsewhere).

Roles in Lymphocyte Biology and Innate Compartments
- CD4+ T cells: IRF4 is essential for Th17 differentiation (binding/promoting Il17a/f, Il21, Rorc) and modulates Treg effector programs; it can either sustain effector functions (e.g., Th1/CTL) or participate in exhaustion programs depending on partner context in the TME (lu2023regulatoryeffectsof pages 1-2, gabele2025elucidatingtherole pages 15-17, gabele2025elucidatingtherolea pages 15-17, gabele2023unveilingirf4steeredregulation pages 17-19). URLs/dates: Frontiers Immunology, Feb 2023, https://doi.org/10.3389/fimmu.2023.1086803; bioRxiv, Sep 2023, https://doi.org/10.1101/2023.09.14.557376.
- B cells/plasma cell biology: IRF4 is a lineage determinant for plasmacytic differentiation and plasma‑cell identity (with BLIMP1/XBP1), and is highly expressed in plasma cells; dysregulation underlies malignant plasma‑cell survival in MM (“IRF4 addiction”). Recent therapeutic studies in MM (below) recapitulate this dependency and its enhancer basis (davis2024mycinhibitionpotentiates pages 15-16, welsh2024transcriptionalheterogeneityovercomes pages 1-3). URLs/dates: Clin Cancer Res, May/Jul 2024, https://doi.org/10.1158/1078-0432.ccr-24-0256; Blood Cancer Discovery, Sep 2024, https://doi.org/10.1158/2643-3230.bcd-23-0062.
- Myeloid and other immune cells: IRF4 regulates programs in macrophages, dendritic cells, and contributes to shaping immunosuppressive cells (e.g., Tregs, MDSCs) in the tumor microenvironment (lu2023regulatoryeffectsof pages 1-2). URL/date: Frontiers Immunology, Feb 2023, https://doi.org/10.3389/fimmu.2023.1086803.

Key Pathways and Crosstalk
- BCR/TCR and NF‑κB: Antigen‑receptor engagement induces IRF4 via NF‑κB (c‑Rel), integrating with AP‑1 and IRF partners at composite elements (gabele2025elucidatingtherole pages 15-17, gabele2025elucidatingtherolea pages 15-17, gabele2023unveilingirf4steeredregulation pages 17-19).
- JAK–STAT: STAT3 cooperates with IRF4 in Th17 programming; IRF4–STAT3 interactions have been detected in Th17 contexts (gabele2023unveilingirf4steeredregulation pages 17-19, gabele2025elucidatingtherole pages 15-17).
- mTOR: mTOR activity modulates IRF4 levels and function during lymphocyte activation and differentiation (gabele2025elucidatingtherole pages 15-17, gabele2025elucidatingtherolea pages 15-17).

Disease Relevance and Genetics
- Multiple myeloma (MM): IRF4 is a lineage oncogene/dependency; the canonical therapeutic axis is CRBN→IKZF1/3 degradation→downregulation of IRF4 and MYC. Failure to suppress IRF4/MYC underlies IMiD resistance; compensatory AP‑1 (BATF) and ETS (ETV4) mechanisms can maintain enhancer activity at IRF4/MYC super‑enhancers, preserving survival programs (davis2024mycinhibitionpotentiates pages 15-16, welsh2024transcriptionalheterogeneityovercomes pages 19-20, welsh2024transcriptionalheterogeneityovercomes pages 1-3, teoh2024resistancetoimmunomodulatory pages 6-7, teoh2024resistancetoimmunomodulatory pages 12-14). URLs/dates: Clin Cancer Res, May/Jul 2024, https://doi.org/10.1158/1078-0432.ccr-24-0256; Blood Cancer Discovery, Sep 2024, https://doi.org/10.1158/2643-3230.bcd-23-0062; Haematologica, Nov 2024, https://doi.org/10.3324/haematol.2024.285636.
- DLBCL/LBCL with IRF4 rearrangement: IRF4‑rearranged LBCL (often pediatric/young adult) shows recurrent IRF4 mutations, frequent NF‑κB pathway co‑alterations (CARD11, CD79B, MYD88), and distinct copy‑number patterns, with prognostic implications (ramiszaldivar2020distinctmolecularprofile pages 1-2). URL/date: Blood, Jan 2020, https://doi.org/10.1182/blood.2019002699.
- Autoimmunity/inflammation and TME: IRF4 coordinates immunity and tolerance, with context‑dependent roles in Th subsets, Treg function, macrophage polarization, and T‑cell exhaustion in tumors (lu2023regulatoryeffectsof pages 1-2, gabele2023unveilingirf4steeredregulation pages 17-19).

Recent Developments (2023–2024) and Applications
- Enhancer‑centric therapies and resistance in MM:
  - Super‑enhancer disrupting combinations: IKZF1/3 degraders (IMiDs/CELMoDs) reduce IRF4/MYC; EP300/CBP catalytic inhibition further suppresses IRF4/MYC and synergizes with IMiDs in vitro/in vivo; however, AP‑1/BATF‑driven maintenance of IRF4/MYC can mediate escape (welsh2024transcriptionalheterogeneityovercomes pages 1-3). URL/date: Blood Cancer Discovery, Sep 2024, https://doi.org/10.1158/2643-3230.bcd-23-0062.
  - Quantitative profiling: 48 myeloma cell lines profiled with pomalidomide (200 nM, 3 days) delineated IMiD sensitivity vs resistance; EP300+IMiD combinations produced deeper MYC/IRF4 suppression but remained vulnerable to BATF‑mediated programs (welsh2024transcriptionalheterogeneityovercomes pages 1-3).
  - Systematic resistance biology and statistics: A 2024 review collated that many Pom‑treated resistant lines remained viable despite marked IKZF1/3 loss; compensatory TFs BATF (upregulated at relapse in a cohort of N=35) and ETV4 (with poorer survival in MMRF CoMMpass N=484) maintained BRD4/P300 occupancy and enhancer function, sustaining IRF4/MYC (teoh2024resistancetoimmunomodulatory pages 6-7). URL/date: Haematologica, Nov 2024, https://doi.org/10.3324/haematol.2024.285636.
  - Downstream targeting of MYC: The MYC inhibitor MYCi975 exerted potent anti‑MM effects in IMiD‑naïve and refractory primary samples, enhanced memory CD8+ T‑cell cytotoxicity, and synergized with pomalidomide to re‑sensitize refractory samples, functionally countering persistent IRF4–MYC programs (davis2024mycinhibitionpotentiates pages 15-16). URL/date: Clin Cancer Res, May/Jul 2024, https://doi.org/10.1158/1078-0432.ccr-24-0256.
  - SUMOylation inhibition: The SUMO E1 inhibitor TAK‑981 reduced IRF4 and c‑MYC through both transcriptional and post‑translational mechanisms and enhanced lenalidomide sensitivity in resistant cell lines and primary MM samples, offering a CRBN‑independent route to downregulate IRF4 (davis2024mycinhibitionpotentiates pages 1-3). URL/date: Cancer Gene Therapy, Mar 2023, https://doi.org/10.1038/s41417-022-00450-9.

Mechanistic Synthesis: IRF4 in Pathways and Partner Networks
- Composite motif logic and partner choice (PU.1/EICE in B cells; BATF/AP‑1/AICE in T cells; AHR/FOXP3/IRF8 in lineage‑specific contexts) underlies IRF4’s target gene selection and explains its divergent roles in effector vs regulatory programs. Enhancer‑biased occupancy and reliance on coactivators (e.g., BRD4, EP300/CBP) connect IRF4 to druggable chromatin machinery (gabele2023unveilingirf4steeredregulation pages 17-19, gabele2023unveilingirf4steeredregulation pages 12-14, welsh2024transcriptionalheterogeneityovercomes pages 1-3, welsh2024transcriptionalheterogeneityovercomes pages 19-20).

Expert Analysis and Opinions from Authoritative Sources
- The 2024 Blood Cancer Discovery study and commentary emphasize that sustained IRF4/MYC expression via transcriptional plasticity (AP‑1/BATF, ETS/ETV4, coactivator compensation) drives IMiD resistance, and that combining IMiDs with p300/CBP inhibition deepens IRF4/MYC suppression but requires strategies to prevent AP‑1‑driven escape (welsh2024transcriptionalheterogeneityovercomes pages 1-3, welsh2024transcriptionalheterogeneityovercomes pages 19-20). URL/date: Blood Cancer Discovery, Sep 2024, https://doi.org/10.1158/2643-3230.bcd-23-0062.
- The 2024 Haematologica review systematically outlines CRBN‑dependent and CRBN‑independent resistance pathways, highlighting that the rate (kinetics) of IKZF1/3 degradation determines IRF4 modulation and clinical response, and pointing to compensatory TFs and metabolic rewiring as targets to collapse IRF4/MYC maintenance (teoh2024resistancetoimmunomodulatory pages 12-14, teoh2024resistancetoimmunomodulatory pages 6-7). URL/date: Haematologica, Nov 2024, https://doi.org/10.3324/haematol.2024.285636.

Relevant Statistics and Data (2023–2024)
- Pomalidomide resistance profiles: An integrative 2024 review reported that a large majority of pomalidomide‑treated resistant MM cell lines remained viable despite substantial IKZF1/3 downregulation; relapse cohorts (N=35) exhibited BATF upregulation, and MMRF CoMMpass (N=484) associated ETV4 upregulation with inferior outcomes, supporting enhancer compensation maintaining IRF4/MYC (teoh2024resistancetoimmunomodulatory pages 6-7). URL/date: Haematologica, Nov 2024, https://doi.org/10.3324/haematol.2024.285636.
- High‑throughput perturbation: 48‑line panel treated 3 days with 200 nM pomalidomide stratified IMiD sensitivity; EP300+IMiD combinations deepened IRF4/MYC repression yet AP‑1 maintained expression in resistant states (welsh2024transcriptionalheterogeneityovercomes pages 1-3). URL/date: Blood Cancer Discovery, Sep 2024, https://doi.org/10.1158/2643-3230.bcd-23-0062.
- Clinical activity benchmarks: Newer CELMoDs have achieved ~30–40% overall response rates (ORR) in IMiD‑refractory MM in clinical studies summarized by Davis et al. (indicating translational viability of further collapsing IRF4/MYC dependencies) (davis2024mycinhibitionpotentiates pages 1-3). URL/date: Clin Cancer Res, May/Jul 2024, https://doi.org/10.1158/1078-0432.ccr-24-0256.

Real‑World Implementations and Therapeutic Implications
- Standard of care and mechanism: IMiDs (lenalidomide, pomalidomide) and next‑generation CELMoDs degrade IKZF1/3 via CRBN, suppressing IRF4 and MYC. Real‑world resistance often reflects failure to extinguish IRF4/MYC due to enhancer‑level plasticity (welsh2024transcriptionalheterogeneityovercomes pages 19-20, davis2024mycinhibitionpotentiates pages 15-16, teoh2024resistancetoimmunomodulatory pages 6-7).
- Emerging strategies:
  - Coactivator targeting: EP300/CBP catalytic inhibition combined with IMiDs to deepen IRF4/MYC suppression; attention to AP‑1 (BATF) activity as a bypass (welsh2024transcriptionalheterogeneityovercomes pages 1-3).
  - Downstream oncogene targeting: MYC inhibition (e.g., MYCi975) synergizing with pomalidomide and boosting CD8+ T‑cell anti‑MM activity (davis2024mycinhibitionpotentiates pages 15-16).
  - Post‑translational modulation: SUMO E1 inhibition (TAK‑981) reduces IRF4/MYC and re‑sensitizes to lenalidomide (davis2024mycinhibitionpotentiates pages 1-3).
- Lymphoma contexts: Recognition and testing for IRF4 rearrangements in LBCL can refine diagnosis and risk (co‑mutations in CARD11, CD79B, MYD88 support NF‑κB‑IRF4 pathway targeting) (ramiszaldivar2020distinctmolecularprofile pages 1-2).

Compliance with Target Identity and Ambiguity Checks
- Gene symbol/organism: All cited work pertains to human IRF4 ortholog functions or directly to human MM/DLBCL biology, matching UniProt Q15306 (Homo sapiens). Domain/family features (IRF family DBD+IAD; nuclear localization; partner‑dependent composite DNA recognition) are consistent across sources and align with UniProt annotations (lu2023regulatoryeffectsof pages 1-2, tatum2025structuralbiophysicaland pages 1-2, gabele2023unveilingirf4steeredregulation pages 17-19, tatum2025structuralbiophysicaland pages 20-23).

Embedded summary of 2023–2024 highlights
| Year | Source (journal; month) | URL / DOI | Focus Area | Key Findings | Relevance to IRF4 |
|---|---|---|---|---|---|
| 2024 | Blood Cancer Discovery (Sep 2024) | https://doi.org/10.1158/2643-3230.bcd-23-0062 (welsh2024transcriptionalheterogeneityovercomes pages 1-3) | IMiD + epigenetic combinations; resistance mechanisms | - EP300/IMiD combination more potently downregulates MYC and IRF4 and shows in vitro/in vivo synergy; - AP-1 factor BATF can maintain MYC/IRF4 and mediate resistance to enhancer-disrupting combos (experimental data across myeloma cell lines) | Demonstrates that targeting enhancer coactivators (EP300/CBP) can suppress the IRF4–MYC oncogenic module but resistance via AP-1/BATF can preserve IRF4 expression (welsh2024transcriptionalheterogeneityovercomes pages 1-3). |
| 2024 | Haematologica (Nov 2024) | https://doi.org/10.3324/haematol.2024.285636 (teoh2024resistancetoimmunomodulatory pages 6-7) | IMiD/CELMoD resistance biology in MM | - Reiterates CRBN→IKZF1/3→IRF4/MYC canonical axis; - Identifies compensatory factors (BATF, ETV4) upregulated at relapse that sustain IRF4/MYC; - Reports quantitative observations on Pom-treated cell lines (e.g., high viability in many resistant lines) | Provides mechanistic and quantitative evidence that maintained IRF4 (via IKZF-independent routes) underlies IMiD resistance and motivates combinations targeting enhancer machinery or compensatory TFs (teoh2024resistancetoimmunomodulatory pages 6-7). |
| 2024 | Clinical Cancer Research (May/Jul 2024) | https://doi.org/10.1158/1078-0432.ccr-24-0256 (davis2024mycinhibitionpotentiates pages 15-16) | MYC targeting to overcome IMiD resistance | - MYC inhibitor (MYCi975) shows potent anti‑MM activity in IMiD‑naïve and refractory primary samples; - MYCi975 synergizes with pomalidomide and enhances CD8+ T-cell cytotoxicity, re-sensitizing refractory samples | Supports downstream targeting of the IRF4–MYC axis (MYC inhibition) as a strategy to overcome IRF4-driven IMiD resistance and harness immune effector cells (davis2024mycinhibitionpotentiates pages 15-16). |
| 2023 | Frontiers in Immunology (Feb 2023) | https://doi.org/10.3389/fimmu.2023.1086803 (lu2023regulatoryeffectsof pages 1-2) | IRF4 regulation across tumor microenvironment and lymphocytes | - IRF4 is immune‑restricted and induced by antigen‑receptor/TCR signaling (not canonical IFN induction); - Central regulator of T/B cell differentiation, effector functions, and implicated in T‑cell exhaustion and TME immunosuppression | Places IRF4 as a context‑dependent transcriptional hub in lymphocytes and the tumor microenvironment, explaining why its modulation affects both anti‑tumor immunity and lymphoid malignancies (lu2023regulatoryeffectsof pages 1-2). |
| 2024 | Nature Reviews Endocrinology (May 2024) | https://doi.org/10.1038/s41574-024-00990-0 (representative review cited via related CD4/Th17 proteogenomics) (gabele2023unveilingirf4steeredregulation pages 17-19) | Transcriptional control of metabolism by IRFs (incl. IRF4) | - IRF family members, including IRF4, regulate chromatin and metabolic gene programs; - IRF4 participates in coupling transcriptional programs to cellular metabolism in immune cells | Highlights mechanistic link between IRF4 transcriptional programs and metabolic reprogramming in immune cells, relevant to Th17 differentiation and effector CD8+/Treg functions (gabele2023unveilingirf4steeredregulation pages 17-19). |
| 2023 | Cancer Gene Therapy (Mar 2023) | https://doi.org/10.1038/s41417-022-00450-9 (davis2024mycinhibitionpotentiates pages 1-3) | SUMOylation and IMiD sensitivity in MM | - SUMO‑E1 inhibition (TAK‑981) decreases IRF4 and c‑MYC levels and enhances lenalidomide sensitivity in resistant MM cell lines and primary samples; - Mechanism: reduced IRF4 transcription and enhanced IRF4 degradation | Demonstrates a non‑CRBN route to downregulate IRF4 (post‑translational/transcriptional) that can resensitize IMiD‑resistant myeloma—supports targeting IRF4 stability/regulation (davis2024mycinhibitionpotentiates pages 1-3). |
| 2020 | Blood (Jan 2020) | https://doi.org/10.1182/blood.2019002699 (ramiszaldivar2020distinctmolecularprofile pages 1-2) | IRF4 rearrangements in large B‑cell lymphoma (disease context) | - LBCL‑IRF4 cases show recurrent IRF4 alterations and frequent co‑alterations in NF‑κB pathway (CARD11, CD79B, MYD88) and distinct CNV patterns; - Defines molecular subset with prognostic implications | Establishes IRF4 rearrangement as a defining genetic lesion in a lymphoma subset, linking dysregulated IRF4 expression to lymphomagenesis and clinical stratification (ramiszaldivar2020distinctmolecularprofile pages 1-2). |
| 2023 | bioRxiv (Sep 2023) | https://doi.org/10.1101/2023.09.14.557376 (gabele2023unveilingirf4steeredregulation pages 17-19) | IRF4 DNA targeting and interactome in Th17/iTreg (mechanism) | - IRF4 is a weak solo DNA binder that relies on partners (PU.1 in B cells; AP‑1/BATF, AHR, FOXP3, IRF8 in T subsets); - Proteomic ChIP/Interactome reveals context‑specific partners and enhancer‑biased binding controlling lineage programs | Mechanistic demonstration that IRF4 target selection and transcriptional outcome are partner‑dependent (explains cell‑type specificity of IRF4 function and implications for therapeutic targeting) (gabele2023unveilingirf4steeredregulation pages 17-19). |


*Table: Compact table summarizing key 2023–2024 findings on IRF4 (mechanisms, disease relevance, and therapeutic strategies) with citations to the evidence used.*

References (with URLs and dates where available)
- Lu J et al. Regulatory effects of IRF4 on immune cells in the tumor microenvironment. Frontiers in Immunology. Feb 2023. https://doi.org/10.3389/fimmu.2023.1086803 (lu2023regulatoryeffectsof pages 1-2).
- Gabele A et al. Unveiling IRF4‑steered regulation of context‑dependent effector programs in Th17 and Treg cells. bioRxiv. Sep 2023. https://doi.org/10.1101/2023.09.14.557376 (gabele2023unveilingirf4steeredregulation pages 17-19, gabele2023unveilingirf4steeredregulation pages 12-14).
- Welsh SJ et al. Transcriptional heterogeneity overcomes super‑enhancer disrupting drug combinations in multiple myeloma. Blood Cancer Discovery. Sep 2024. https://doi.org/10.1158/2643-3230.bcd-23-0062 (welsh2024transcriptionalheterogeneityovercomes pages 1-3, welsh2024transcriptionalheterogeneityovercomes pages 19-20).
- Teoh PJ et al. Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond. Haematologica. Nov 2024. https://doi.org/10.3324/haematol.2024.285636 (teoh2024resistancetoimmunomodulatory pages 6-7, teoh2024resistancetoimmunomodulatory pages 17-18, teoh2024resistancetoimmunomodulatory pages 12-14).
- Davis LN et al. MYC inhibition potentiates CD8+ T cells against multiple myeloma and overcomes immunomodulatory drug resistance. Clinical Cancer Research. May/Jul 2024. https://doi.org/10.1158/1078-0432.ccr-24-0256 (davis2024mycinhibitionpotentiates pages 15-16, davis2024mycinhibitionpotentiates pages 1-3).
- Du L et al. SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide. Cancer Gene Therapy. Mar 2023. https://doi.org/10.1038/s41417-022-00450-9 (davis2024mycinhibitionpotentiates pages 1-3).
- Ramis‑Zaldivar JE et al. Distinct molecular profile of IRF4‑rearranged large B‑cell lymphoma. Blood. Jan 2020. https://doi.org/10.1182/blood.2019002699 (ramiszaldivar2020distinctmolecularprofile pages 1-2).
- Tatum NJ et al. Structural, biophysical and biological analysis of IRF4 DBD mutations. bioRxiv. Mar 2025. https://doi.org/10.1101/2025.03.12.642038 (tatum2025structuralbiophysicaland pages 1-2, tatum2025structuralbiophysicaland pages 20-23).

Notes on evidence strength: Several mechanistic and translational claims are supported by 2023–2024 peer‑reviewed studies (Frontiers Immunology 2023; Blood Cancer Discovery 2024; Clinical Cancer Research 2024; Haematologica 2024). Structural DBD and some mechanistic details rely on preprints (bioRxiv 2025) and should be interpreted with caution until peer review (tatum2025structuralbiophysicaland pages 1-2, tatum2025structuralbiophysicaland pages 20-23).

References

1. (lu2023regulatoryeffectsof pages 1-2): Jing Lu, Taotao Liang, Ping Li, and Qing-song Yin. Regulatory effects of irf4 on immune cells in the tumor microenvironment. Frontiers in Immunology, Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1086803, doi:10.3389/fimmu.2023.1086803. This article has 33 citations and is from a peer-reviewed journal.

2. (gabele2025elucidatingtherole pages 15-17): AMC Gabele. Elucidating the role of the transcription factor interferon regulatory factor 4 in differentiated t helper 17 and regulatory t cells. Unknown journal, 2025.

3. (gabele2025elucidatingtherolea pages 15-17): AMC Gabele. Elucidating the role of the transcription factor interferon regulatory factor 4 in differentiated t helper 17 and regulatory t cells. Unknown journal, 2025.

4. (tatum2025structuralbiophysicaland pages 1-2): Natalie J. Tatum, Rebecca Scott, Gina M. Doody, Ian Hickson, Claire E. Jennings, Mathew P. Martin, Reuben M. Tooze, Julie A. Tucker, Anita Wittner, Lan-Zhen Wang, Eleanor K. Wright, Stephen R. Wedge, and Martin E.M. Noble. Structural, biophysical and biological analysis and characterisation of irf4 dna-binding domain mutations associated with multiple myeloma. bioRxiv, Mar 2025. URL: https://doi.org/10.1101/2025.03.12.642038, doi:10.1101/2025.03.12.642038. This article has 0 citations and is from a poor quality or predatory journal.

5. (tatum2025structuralbiophysicaland pages 20-23): Natalie J. Tatum, Rebecca Scott, Gina M. Doody, Ian Hickson, Claire E. Jennings, Mathew P. Martin, Reuben M. Tooze, Julie A. Tucker, Anita Wittner, Lan-Zhen Wang, Eleanor K. Wright, Stephen R. Wedge, and Martin E.M. Noble. Structural, biophysical and biological analysis and characterisation of irf4 dna-binding domain mutations associated with multiple myeloma. bioRxiv, Mar 2025. URL: https://doi.org/10.1101/2025.03.12.642038, doi:10.1101/2025.03.12.642038. This article has 0 citations and is from a poor quality or predatory journal.

6. (gabele2023unveilingirf4steeredregulation pages 17-19): Anna Gabele, Maximilian Sprang, Mert Cihan, Sarah Dietzen, Matthias Klein, Gregory Harms, Tanja Ziesmann, Katrin Pape, Beatrice Wasser, David Gomez-Zepeda, Kathrin Braband, Michael Delacher, Niels Lemmermann, Stefan Bittner, Miguel A. Andrade-Navarro, Stefan Tenzer, Tobias Bopp, and Ute Distler. Unveiling irf4-steered regulation of context-dependent effector programs in th17 and treg cells. bioRxiv, Sep 2023. URL: https://doi.org/10.1101/2023.09.14.557376, doi:10.1101/2023.09.14.557376. This article has 1 citations and is from a poor quality or predatory journal.

7. (gabele2023unveilingirf4steeredregulation pages 12-14): Anna Gabele, Maximilian Sprang, Mert Cihan, Sarah Dietzen, Matthias Klein, Gregory Harms, Tanja Ziesmann, Katrin Pape, Beatrice Wasser, David Gomez-Zepeda, Kathrin Braband, Michael Delacher, Niels Lemmermann, Stefan Bittner, Miguel A. Andrade-Navarro, Stefan Tenzer, Tobias Bopp, and Ute Distler. Unveiling irf4-steered regulation of context-dependent effector programs in th17 and treg cells. bioRxiv, Sep 2023. URL: https://doi.org/10.1101/2023.09.14.557376, doi:10.1101/2023.09.14.557376. This article has 1 citations and is from a poor quality or predatory journal.

8. (davis2024mycinhibitionpotentiates pages 15-16): Lorraine N. Davis, Zachary J. Walker, Lauren T. Reiman, Sarah E. Parzych, Brett M. Stevens, Craig T. Jordan, Peter A. Forsberg, and Daniel W. Sherbenou. Myc inhibition potentiates cd8+ t cells against multiple myeloma and overcomes immunomodulatory drug resistance. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:3023-3035, May 2024. URL: https://doi.org/10.1158/1078-0432.ccr-24-0256, doi:10.1158/1078-0432.ccr-24-0256. This article has 9 citations.

9. (welsh2024transcriptionalheterogeneityovercomes pages 1-3): Seth J. Welsh, Benjamin G. Barwick, Erin W. Meermeier, Daniel L. Riggs, Chang-Xin Shi, Yuan Xiao Zhu, Meaghen E. Sharik, Megan T. Du, Leslie D. Abrego Rocha, Victoria M. Garbitt, Caleb K. Stein, Joachim L. Petit, Nathalie Meurice, Yuliza Tafoya Alvarado, Rodrigo Fonseca, Kennedi T. Todd, Sochilt Brown, Zachery J. Hammond, Nicklus H. Cuc, Courtney Wittenberg, Camille Herzog, Anna V. Roschke, Yulia N. Demchenko, Wei-dong D. Chen, Peng Li, Wei Liao, Warren J. Leonard, Sagar Lonial, Nizar J. Bahlis, Paola Neri, Lawrence H. Boise, Marta Chesi, and P. Leif Bergsagel. Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma. Blood Cancer Discovery, 5:34-55, Sep 2024. URL: https://doi.org/10.1158/2643-3230.bcd-23-0062, doi:10.1158/2643-3230.bcd-23-0062. This article has 39 citations and is from a peer-reviewed journal.

10. (welsh2024transcriptionalheterogeneityovercomes pages 19-20): Seth J. Welsh, Benjamin G. Barwick, Erin W. Meermeier, Daniel L. Riggs, Chang-Xin Shi, Yuan Xiao Zhu, Meaghen E. Sharik, Megan T. Du, Leslie D. Abrego Rocha, Victoria M. Garbitt, Caleb K. Stein, Joachim L. Petit, Nathalie Meurice, Yuliza Tafoya Alvarado, Rodrigo Fonseca, Kennedi T. Todd, Sochilt Brown, Zachery J. Hammond, Nicklus H. Cuc, Courtney Wittenberg, Camille Herzog, Anna V. Roschke, Yulia N. Demchenko, Wei-dong D. Chen, Peng Li, Wei Liao, Warren J. Leonard, Sagar Lonial, Nizar J. Bahlis, Paola Neri, Lawrence H. Boise, Marta Chesi, and P. Leif Bergsagel. Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma. Blood Cancer Discovery, 5:34-55, Sep 2024. URL: https://doi.org/10.1158/2643-3230.bcd-23-0062, doi:10.1158/2643-3230.bcd-23-0062. This article has 39 citations and is from a peer-reviewed journal.

11. (teoh2024resistancetoimmunomodulatory pages 6-7): Phaik Ju Teoh, Mun Yee Koh, Constantine Mitsiades, Sarah Gooding, and Wee Joo Chng. Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond. Haematologica, 110:1074-1091, Nov 2024. URL: https://doi.org/10.3324/haematol.2024.285636, doi:10.3324/haematol.2024.285636. This article has 3 citations.

12. (teoh2024resistancetoimmunomodulatory pages 12-14): Phaik Ju Teoh, Mun Yee Koh, Constantine Mitsiades, Sarah Gooding, and Wee Joo Chng. Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond. Haematologica, 110:1074-1091, Nov 2024. URL: https://doi.org/10.3324/haematol.2024.285636, doi:10.3324/haematol.2024.285636. This article has 3 citations.

13. (ramiszaldivar2020distinctmolecularprofile pages 1-2): Joan Enric Ramis-Zaldivar, Blanca Gonzalez-Farré, Olga Balagué, Verónica Celis, Ferran Nadeu, Julia Salmerón-Villalobos, Mara Andrés, Idoia Martin-Guerrero, Marta Garrido-Pontnou, Ayman Gaafar, Mariona Suñol, Carmen Bárcena, Federico Garcia-Bragado, Maitane Andión, Daniel Azorín, Itziar Astigarraga, Maria Sagaseta de Ilurdoz, Constantino Sábado, Soledad Gallego, Jaime Verdú-Amorós, Rafael Fernandez-Delgado, Vanesa Perez, Gustavo Tapia, Anna Mozos, Montserrat Torrent, Palma Solano-Páez, Alfredo Rivas-Delgado, Ivan Dlouhy, Guillem Clot, Anna Enjuanes, Armando López-Guillermo, Pallavi Galera, Matthew J. Oberley, Alanna Maguire, Colleen Ramsower, Lisa M. Rimsza, Leticia Quintanilla-Martinez, Elaine S. Jaffe, Elías Campo, and Itziar Salaverria. Distinct molecular profile of irf4-rearranged large b-cell lymphoma. Blood, 135:274-286, Jan 2020. URL: https://doi.org/10.1182/blood.2019002699, doi:10.1182/blood.2019002699. This article has 128 citations and is from a highest quality peer-reviewed journal.

14. (davis2024mycinhibitionpotentiates pages 1-3): Lorraine N. Davis, Zachary J. Walker, Lauren T. Reiman, Sarah E. Parzych, Brett M. Stevens, Craig T. Jordan, Peter A. Forsberg, and Daniel W. Sherbenou. Myc inhibition potentiates cd8+ t cells against multiple myeloma and overcomes immunomodulatory drug resistance. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:3023-3035, May 2024. URL: https://doi.org/10.1158/1078-0432.ccr-24-0256, doi:10.1158/1078-0432.ccr-24-0256. This article has 9 citations.

15. (teoh2024resistancetoimmunomodulatory pages 17-18): Phaik Ju Teoh, Mun Yee Koh, Constantine Mitsiades, Sarah Gooding, and Wee Joo Chng. Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond. Haematologica, 110:1074-1091, Nov 2024. URL: https://doi.org/10.3324/haematol.2024.285636, doi:10.3324/haematol.2024.285636. This article has 3 citations.

## Citations

1. tatum2025structuralbiophysicaland pages 20-23
2. lu2023regulatoryeffectsof pages 1-2
3. ramiszaldivar2020distinctmolecularprofile pages 1-2
4. welsh2024transcriptionalheterogeneityovercomes pages 1-3
5. teoh2024resistancetoimmunomodulatory pages 6-7
6. davis2024mycinhibitionpotentiates pages 15-16
7. davis2024mycinhibitionpotentiates pages 1-3
8. gabele2025elucidatingtherole pages 15-17
9. gabele2025elucidatingtherolea pages 15-17
10. tatum2025structuralbiophysicaland pages 1-2
11. welsh2024transcriptionalheterogeneityovercomes pages 19-20
12. teoh2024resistancetoimmunomodulatory pages 12-14
13. teoh2024resistancetoimmunomodulatory pages 17-18
14. https://doi.org/10.3389/fimmu.2023.1086803;
15. https://doi.org/10.1101/2025.03.12.642038.
16. https://doi.org/10.1101/2023.09.14.557376.
17. https://doi.org/10.1158/1078-0432.ccr-24-0256;
18. https://doi.org/10.1158/2643-3230.bcd-23-0062.
19. https://doi.org/10.3389/fimmu.2023.1086803.
20. https://doi.org/10.1158/2643-3230.bcd-23-0062;
21. https://doi.org/10.3324/haematol.2024.285636.
22. https://doi.org/10.1182/blood.2019002699.
23. https://doi.org/10.1158/1078-0432.ccr-24-0256.
24. https://doi.org/10.1038/s41417-022-00450-9.
25. https://doi.org/10.1158/2643-3230.bcd-23-0062
26. https://doi.org/10.3324/haematol.2024.285636
27. https://doi.org/10.1158/1078-0432.ccr-24-0256
28. https://doi.org/10.3389/fimmu.2023.1086803
29. https://doi.org/10.1038/s41574-024-00990-0
30. https://doi.org/10.1038/s41417-022-00450-9
31. https://doi.org/10.1182/blood.2019002699
32. https://doi.org/10.1101/2023.09.14.557376
33. https://doi.org/10.1101/2025.03.12.642038
34. https://doi.org/10.3389/fimmu.2023.1086803,
35. https://doi.org/10.1101/2025.03.12.642038,
36. https://doi.org/10.1101/2023.09.14.557376,
37. https://doi.org/10.1158/1078-0432.ccr-24-0256,
38. https://doi.org/10.1158/2643-3230.bcd-23-0062,
39. https://doi.org/10.3324/haematol.2024.285636,
40. https://doi.org/10.1182/blood.2019002699,